Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.
Freeman R, Foley S, Rosa Arias J, Vicente E, Grill R, Kachlirova Z, Stari A, Huang M, Choudhury N. Freeman R, et al. Among authors: choudhury n. Curr Med Res Opin. 2018 May;34(5):785-793. doi: 10.1080/03007995.2017.1419170. Epub 2018 Jan 10. Curr Med Res Opin. 2018. PMID: 29254376
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR. Kaplan SA, et al. Among authors: choudhury n. J Urol. 2020 Jun;203(6):1163-1171. doi: 10.1097/JU.0000000000000738. Epub 2020 Jan 2. J Urol. 2020. PMID: 31895002 Clinical Trial.
Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.
Herschorn S, McVary KT, Cambronero Santos J, Foley S, Kristy RM, Choudhury N, Hairston J, Kaplan SA. Herschorn S, et al. Among authors: choudhury n. Urology. 2021 Jan;147:235-242. doi: 10.1016/j.urology.2020.09.040. Epub 2020 Oct 10. Urology. 2021. PMID: 33045287 Free article. Clinical Trial.
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E. Chapple CR, et al. Among authors: choudhury n. Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18. Eur Urol. 2020. PMID: 31635815 Free article. Clinical Trial.
Reply by Authors.
Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR. Kaplan SA, et al. Among authors: choudhury n. J Urol. 2020 Jun;203(6):1171. doi: 10.1097/JU.0000000000000738.02. Epub 2020 Mar 19. J Urol. 2020. PMID: 32191170 No abstract available.
562 results